๐ข ๐๐๐๐ ๐๐: Tempus AI to Acquire Personalis in $๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง Deal - $Tempus AI(TEM.US) $Personalis(PSNL.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐๐ฆ๐ฉ๐ฎ๐ฌ ๐๐ will acquire ๐๐๐ซ๐ฌ๐จ๐ง๐๐ฅ๐ข๐ฌ in a $๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง transaction.โค Personalis shareholders will receive $๐๐.๐๐ per common share.โค Acquisition expands Tempus' ๐ฆ๐ข๐ง๐ข๐ฆ๐๐ฅ ๐ซ๐๐ฌ๐ข๐๐ฎ๐๐ฅ ๐๐ข๐ฌ๐๐๐ฌ (๐๐๐) capabilities.โค Deal combines Personalis' MRD technology with Tempus' ๐๐ and multimodal data platform.โค Tempus says MRD represents a $๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง market opportunity.โค Companies have partnered since ๐๐จ๐ฏ๐๐ฆ๐๐๐ซ ๐๐๐๐.โค Personalis' NeXT Personalยฎ test offers ๐ฎ๐ฅ๐ญ๐ซ๐๐ฌ๐๐ง๐ฌ๐ข๐ญ๐ข๐ฏ๐ cancer recurrence monitoring.โค Medicare currently covers the test in ๐ญ๐ก๐ซ๐๐ indications.โค Acquisition aims to expand personalized cancer monitoring and biomarker discovery.๐ ๐๐ฑ๐ฉ๐๐ซ๐ญ ๐๐ญ๐๐ญ๐๐ฆ๐๐ง๐ญ๐ฌ:๐๐ซ๐ข๐ ๐๐๐๐ค๐จ๐๐ฌ๐ค๐ฒ, CEO of Tempus:โMRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs. Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure. With clinical adoption and reimbursement momentum building, we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting."๐๐ก๐ซ๐ข๐ฌ ๐๐๐ฅ๐ฅ, CEO of Personalis:โWe believe this transaction represents an exciting next chapter for Personalis. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners. After conducting an exhaustive process, we are confident Tempusโ offer provides the most value to our shareholders and the fastest path to bringing Personalisโ industry-leading tests to patients suffering from cancer.โ